Black ethnicity is associated with worse pregnancy outcomes in women with chronic hypertension. Pre-24 existing endothelial and renal dysfunction, and poor placentation may contribute but pathophysiological 25 mechanisms underpinning increased risk are poorly understood. This cohort study aimed to investigate the 26 relationship between ethnicity, superimposed pre-eclampsia and longitudinal changes in markers of 27 endothelial, renal and placental dysfunction in women with chronic hypertension. Plasma concentrations of 28 placental growth factor (PlGF), syndecan-1, renin, aldosterone, and urinary angiotensinogen:creatinine ratio 29 (AGTCR), protein:creatinine ratio (PCR) and albumin:creatinine ratio (ACR) were quantified during pregnancy 30 and postpartum in women with chronic hypertension. Comparisons of longitudinal biomarker 31 concentrations were made using log-transformation and random effects logistic regression allowing for 32 gestation. Of 117 women, superimposed preeclampsia was diagnosed in 21% (n=25), with 24% (n=6) having 33 an additional diagnosis of diabetes. The cohort included 63 (54%) women who self-identified as of Black 34 ethnicity. PlGF concentrations were 67% lower (95% CI -79% to -48%), and AGTCR, PCR and ACR were higher 35 over gestation, in women with subsequent superimposed preeclampsia (compared to those without 36 superimposed preeclampsia). PlGF <100 pg/mL at 20-23.9 weeks' gestation predicted subsequent 37 birthweight <3 rd centile with 88% sensitivity (95% CI 47%-100%) and 83% specificity (95% CI 70%-92%). Black 38 women had 43% lower renin (95% CI -58% to -23%) and 41% lower aldosterone (95%CI -45% to -15%) 39 concentrations over gestation. Changes in placental (PlGF) and renal (AGTCR/PCR/ACR) biomarkers predated 40 adverse pregnancy outcome. Ethnic variation in the renin-angiotensin-aldosterone system exists in women 41 with chronic hypertension in pregnancy and may be important in treatment selection. 42
INTRODUCTION 44
Chronic hypertension is estimated to affect 3% of pregnancies (41, 42) and is associated with adverse 45 maternal and perinatal outcome. (5, 6) A recent systematic review by Bramham and colleagues (2014) 46 reported a relative risk of superimposed preeclampsia of 7.7 (95% confidence interval 5.7 to 10.1) compared 47 to the risk of preeclampsia in the general pregnant population.(6) Adverse perinatal outcomes such as 48 stillbirth, fetal growth restriction and prematurity are also more common in women with chronic 49 hypertension and occur independently from a diagnosis of superimposed preeclampsia. (1, 13, 43) Women of 50 Black ethnicity, compared to women of White ethnicity with chronic hypertension, have an increased risk of 51 superimposed preeclampsia,(13) which may be contributory, but greater understanding of the interplay of 52 known biomarkers and ethnicity in women with chronic hypertension may provide insight into 53 pathophysiological mechanisms. 54 55 Preeclampsia is characterized by placental and maternal vascular dysfunction.(44) Placental growth factor 56 (PlGF) and syndecan-1 are placental and endothelial biomarkers that have previously been shown to 57 decrease in concentration in the maternal circulation prior to the onset of the clinical signs of 58 preeclampsia. (23, 30, 31) A recent study by Chappell and colleagues (2013) has demonstrated that low PlGF, 59 in women presenting before 35 weeks' gestation with suspected preeclampsia, has high sensitivity and 60 negative predictive value for preeclampsia within 14 days.(12) Diagnosing superimposed preeclampsia in 61 women with chronic hypertension is challenging because gestational progression of hypertension may occur 62 in response to the physiological changes in pregnancy, without the sequelae of preeclampsia. Variation in 63 these biomarkers over gestation in women with chronic hypertension requires further exploration. 64
Biomarker variation in chronic hypertensive pregnancy the RAAS and other renal biomarkers (protein: creatinine ratio (PCR) and albumin: creatinine ratio (ACR)) 70 have been demonstrated in preeclampsia; (7, 15) however there are limited data from longitudinal cohorts 71 examining these biomarkers in pregnant women with chronic hypertension.(4) The impact of ethnicity on 72 these biomarkers in pregnancy also requires exploration. Black women are more likely to have low renin 73 hypertension(40) and ethnic differences in RAAS function in pregnancy may partly explain disparity observed 74 in clinical outcome. (8, 38) 75 76 This study aimed to investigate the longitudinal variation in endothelial and renal biomarkers in women with 77 chronic hypertension in pregnancy, and the impact of subsequent superimposed preeclampsia and ethnicity 78 on these biomarkers. Biomarker variation in chronic hypertensive pregnancy Urinary angiotensinogen concentrations were determined using a solid phase sandwich ELISA kit Biological Laboratories, Gunma, Japan) according to manufacturer 's instructions.(27) The urinary 144 angiotensinogen concentrations were then normalised to urinary creatinine to provide AGTCR. Urinary 145 creatinine, protein and albumin reagents were supplied by Siemens Healthcare Diagnostics Ltd (Camberley, 146 UK) . Urinary creatinine reacted with picric acid under alkaline conditions to form a red Janovsky complex 147 (the Jaffé reaction).(34) The initial rate of absorbance change was measured at a wavelength of 505 nm and 148 compared to that of a known calibrant. This was directly proportional to the concentration of creatinine in 149 the sample. A blank reaction rate was performed using reagent 1 (sodium hydroxide, before picrate 150 addition) to minimise interference from bilirubin. Urinary protein forms a blue coloured complex with 151 pyrogallol red, under acid conditions and in the presence of molybdate ions. (22) The absorbance of this 152 complex was measured at 596 nm, and related to that of a previous calibration assay. Urine albumin was 153 measured using a polyethylglycol enhanced immunoturbidimetric method a commonly used assay 154 technique.(10) The sample was diluted and then reacted with antiserum to form a precipitate that was 155 measured turbidimetrically at 340nm. Urine albumin was measured on the Siemens Advia 2400 analyser. 156
Biomarker variation in chronic hypertensive pregnancy compared between subgroups in analyses A and B using t-tests or Mann-Whitney test for continuous 168 variables depending on the distributions and Fisher's exact test for categorical variables. Mean post-169 enrollment systolic and diastolic blood pressure were calculated using the trapezium method of analysing 170 the area under the curve for each woman. Variation in longitudinal endothelial and renal biomarkers for 171 analyses A and B was assessed using random effects GLS regression with robust standard errors(3) on log-172 transformed data allowing for gestation effects. Logged estimates with 95% confidence intervals of the 173 geometric means and of their ratios to the reference group in each analysis were calculated. Standard 174 mathematic methods converted these to percentage differences between groups: percent difference = 175 (exp[parameter]-1) x 100%. An interaction test examining the correlation between ethnicity, diagnosis of 176 superimposed preeclampsia and gestation was performed using a random-effects regression model, 177 wherever significant ethnic differences in biomarker concentration were demonstrated. 178
179

RESULTS
180
The cohort recruited to the study included 121 women with singleton pregnancies and chronic hypertension 181 ( Figure 1 ). Longitudinal samples (332 in total) were obtained in 117 (97%) women; outcome data were 182 unavailable for four (3.3%) women (two women lost to follow-up and two withdrew from the study). For 183 analysis A, the cohort was divided into women diagnosed with superimposed preeclampsia and compared 184 with women who were not diagnosed with superimposed preeclampsia (n=25 versus n=92) and for analysis 185 B, the cohort was divided into women self-identifying as of Black ethnicity versus women self-identifying as 186 of non-Black ethnicity (n=63 versus n=54). 187
188
The baseline demographics of the women who provided samples for the analyses are detailed in Table 1 . 189
The women who developed superimposed preeclampsia, compared to those who did not, were younger (33 190 years versus 36 years; p 0.04), and a higher proportion of the women who developed superimposed 191 preeclampsia, compared to those who did not, had pre-existing diabetes mellitus (24% versus 6.5%; p 0.02). 192
Fewer black women were nulliparous, compared to non-Black women (6.3% versus 33%; p 0.0003), and the 193 Biomarker variation in chronic hypertensive pregnancy diastolic blood pressure was higher in Black women than non-Black women at antenatal booking (88 mmHg 194 versus 85 mmHg; p 0.03). Otherwise the groups were comparable at baseline. 195
196
Maternal and perinatal outcomes for the cohort as a whole, in addition to the subgroups within analysis A 197 (superimposed preeclampsia versus chronic hypertensive controls) and B (Black women versus non-Black 198 women), are shown in Table 2 and 3. There were no differences in outcome between labetalol and 199 nifedipine arms of the trial. Superimposed preeclampsia was diagnosed in 21% (n=25) of the whole cohort of 200 women with chronic hypertension, with 31% (n=36) of infants being born before 37 weeks' gestation and 201 91% (n=106) livebirths. Of the 106 livebirths, 29% (n=31) had a birthweight below the 10 th centile (n=18 of 202 these infants were born before 37 weeks' gestation), 15% (n=16) had a birthweight below the 3 rd centile, and 203 23% (n=25) required admission to the neonatal unit. 204
205
Within the subgroups, the greatest differences in maternal and perinatal outcome were seen in the women 206 with chronic hypertension who developed superimposed preeclampsia compared to chronic hypertensive 207 controls. The mean systolic (137 mmHg versus 132 mmHg; p 0.005) and mean diastolic (87 mmHg versus 84 208 mmHg; p 0.002) blood pressures were higher in the women with superimposed preeclampsia compared to 209 those with no superimposed preeclampsia. Women diagnosed with superimposed preeclampsia were more 210 likely to have an emergency Caesarean birth, compared to those without superimposed preeclampsia (64% 211 versus 42%; p 0.03). Additionally, preterm birth before 37 weeks' gestation occurred more frequently in 212 women with superimposed preeclampsia than without (56% versus 24%; p 0.003). The infants born to 213 mothers who were diagnosed with superimposed preeclampsia, compared to those who were not, had 214 lower birthweights (2270g versus 3020g; p <0.0001) and were more likely to be admitted to the neonatal 215 unit (52% versus 14%; p 0.0007). The only significant difference in maternal and perinatal outcome found 216 between the women of Black ethnicity and those of non-Black ethnicity, was higher mean post-enrollment 217 diastolic blood pressure (Black women: 86 mmHg versus non-Black women: 83 mmHg; p 0.03). 218 
Endothelial biomarkers 220
The longitudinal changes in PlGF and syndecan-1 are displayed in Figures 2, 3 and 4. Analysis A 221 (superimposed preeclampsia versus no superimposed preeclampsia) demonstrated that PlGF concentration 222 increased across gestation in the women who did not develop SPE to a peak mean value of 363 pg/mL at 28 223 to 31.9 weeks' gestation, but in the women who developed subsequent SPE the peak mean PlGF was 105 224 pg/mL and occurred at 20 to 23.9 weeks' gestation ( Figure 2 ).Comparative analysis demonstrated that the 225 PlGF concentrations were 67% lower (95% confidence interval -79% to -48%; p=<0.001) in women who 226 developed superimposed preeclampsia compared to those who did not. In analysis B, PlGF concentration 227 increased across gestation in women of Black ethnicity and women of non-Black ethnicity ( Figure 2 ). There 228 was no overall difference in concentrations between groups (-2%; 95% confidence interval -43% to 68%; 229 p=0.94). 230 231 Given the high proportion of infants born below the 3 rd and 10 th centile in this cohort of women with chronic 232 hypertension, an additional analysis assessed the gestational changes in each biomarker and birthweight 233 centile. The only biomarker demonstrating a significant association with birthweight centile category (<3 rd , 234 3 rd to 10 th and >10 th ) was PlGF ( Figure 3 ). PlGF <100 pg/mL at 20 to 23.9 weeks' gestation to predict 235 subsequent birthweight <3 rd centile demonstrated 88% sensitivity (95% confidence interval 47% to 100%), 236 83% specificity (95% confidence interval 70% to 92%), and the negative predictive value was 98% (95% 237 confidence interval 88% to 100%). 238 239 Syndecan-1 concentrations increased significantly across gestation in all subgroups (p <0.0001) ( Figure 4 ). 240
Postpartum syndecan-1 concentrations were 83% lower (95% confidence interval -87% to -78%; p=<0.001) 241 than antenatal syndecan-1 concentrations. No significant differences were found in syndecan-1 242 concentrations either in women with chronic hypertension who did and did not develop superimposed 243 Biomarker variation in chronic hypertensive pregnancy preeclampsia (-5%; 95% confidence interval -24% to 18%; p=0.62), or in women with chronic hypertension of 244 Black or non-Black ethnicity (-5%; 95% confidence interval -22% to 15%; p=0.59). 245 246
Renal biomarkers 247
Plasma renin concentrations did not vary significantly over the gestation studied (12 to 35.9 weeks) (Figure 248 5); however antepartum renin concentrations were significantly higher than in samples taken six weeks 249 postpartum (p <0.0001). In the women who developed superimposed preeclampsia, the mean renin 250 concentrations at each gestational time point tended to be higher than in women who did not develop 251 superimposed preeclampsia until 32 to 35.9 weeks' gestation. However, these differences were not 252 statistically significant when longitudinal measures were compared (34%; 95% confidence interval -2% to 253 82%; p=0.06). In Black women with chronic hypertension with or without superimposed preeclampsia, the 254 mean renin concentrations were significantly lower across gestation compared to women of non-Black 255 ethnicity (-43%; 95% confidence interval -58% to -23%; p=<0.001). Further analysis explored the differences 256 between gestational renin concentrations and six-week postpartum renin concentrations. In women of Black 257 ethnicity, postpartum renin concentrations were 81% lower (95% confidence interval -91% to -58%; 258 p=<0.001) compared with antenatal concentrations and in non-Black women the postpartum renin 259 concentrations were 54% lower (95% confidence interval -73% to -22%; p=0.004) than antenatal values in 260 this group. An interaction test examined the potential relationship between ethnicity, gestation and 261 diagnosis of superimposed preeclampsia and did not demonstrate a significant correlation. 262 263 Aldosterone concentrations were 57% higher (95% confidence interval 43% to 68%; p=<0.001) in pregnancy 264 than at six weeks postpartum. No significant difference was found in aldosterone concentrations between 265 the women who did and did not develop superimposed preeclampsia (5%; 95% confidence interval -20% to 266 39%; p=0.73) ( Figure 6 ). In the women of Black ethnicity compared to those of non-Black ethnicity who did 267 or did not develop superimposed preeclampsia, aldosterone concentrations in pregnancy were 31% lower 268 (95% confidence interval -45% to -15%; p=0.001). There was no difference in aldosterone concentrations 269 Biomarker variation in chronic hypertensive pregnancy between ethnic groups at the six-week postpartum timepoint (13%; 95% confidence interval -46% to 131%; 270 p=0.72). Across gestation, aldosterone concentrations increased by 70% in the women of non-Black ethnicity 271 (95% confidence interval 39% to 209%; p=<0.001); however in the Black women no significant increase in 272 aldosterone concentrations was demonstrated across gestation (13%; 95% confidence interval -7% to 37%; 273 p=0.23). An interaction test explored the potential association of ethnicity, gestation and diagnosis of 274 superimposed preeclampsia and did not demonstrate a significant correlation. Aldosterone: renin ratio was 275 calculated and compared for analysis A and B, but no association was seen. 276 277 Women with chronic kidney disease were excluded from the analysis of the urinary biomarkers (n=11). 278
Urinary AGTCR increased across gestation and was significantly lower at six weeks postpartum (-79%; 95% 279 confidence interval -86% to -69%; p=<0.001). In the women with superimposed preeclampsia, compared to 280 chronic hypertensive controls, the AGTCR was 63% higher across gestation (95% confidence interval 10% to 281 142%; p=0.02) ( Figure 7 ). There was no difference between the AGTCR in women of Black or non-Black 282 ethnicity (12%; 95% confidence interval -22% to 61%; p=0.53). No correlation between the systemic RAAS 283 (plasma renin and aldosterone) or the intra-renal RAS (AGTCR) was found. 284 285 PCR increased across gestation in all subgroups (51%; 95% confidence interval 24% to 84%; p=<0.001) and 286 returned to levels comparable to the 12 to 16.9 week mean ratio by six weeks postpartum. PCR was overall 287 significantly higher across gestation in the women who subsequently developed superimposed preeclampsia 288 compared to those who did not (29%; 95% confidence interval 5% to 57%; p=0.01) ( Figure 8 ). There was no 289 significant difference in PCR across gestation in Black and non-Black women (4%; 95% confidence interval -290 14% to 24%; p=0.71). 291 292 ACR did not vary significantly across gestation in the cohort as a whole (20%; 95% confidence interval -10% 293 to 59%; p=0.22). However, in the women who were subsequently diagnosed with superimposed 294 preeclampsia compared to chronic hypertensive controls, ACR was higher (123%; 95% confidence interval 295 Biomarker variation in chronic hypertensive pregnancy 67% to 197%; p=<0.001) ( Figure 9 ). There was no difference in ACR when women of Black and non-Black 296 ethnicity were compared (10%; 95% confidence interval -19% to 50%; p=0.55). 297
298
DISCUSSION 299
This study has confirmed that low PlGF across gestation in women with chronic hypertension in pregnancy 300 predates the clinical presentation of superimposed preeclampsia and fetal growth restriction. To our 301 knowledge, this is the first study in women with chronic hypertension to demonstrate the potential utility of 302
PlGF as a predictive tool for fetal growth restriction; with further validation, PlGF concentrations <100 pg/mL 303 at 20 to 23.9 weeks' gestation may aid risk stratification and timing of ultrasound surveillance in this group. 304 Furthermore, the potential utility of PlGF in the diagnosis and prediction of superimposed preeclampsia in 305 women with chronic hypertension, a group in whom the diagnosis is most challenging given the pre-existing 306 hypertension, is demonstrated. Low PlGF concentrations across gestation in women who develop 307 preeclampsia has been demonstrated in women without chronic hypertension.(31) It has been proposed 308 that the imbalance in angiogenic markers observed in women with preeclampsia was greater than observed 309 in women with superimposed preeclampsia,(14) but the findings of our study support comparable 310 pathophysiology underpinning preeclampsia in women with and without chronic hypertension and reported 311 elsewhere.(35) 312
313
The high incidence of adverse maternal and perinatal outcomes in women with chronic hypertension in 314 pregnancy is highlighted by this study with 21% of women developing superimposed preeclampsia, 315 comparable with the findings of other studies ranging from 17 to 25%. (33, 39, 41, 42) The incidence of 316 superimposed preeclampsia is this cohort may relate in part to the number of participants with diabetes, as 317 demonstrated by the significant difference in the proportion of women with diabetes and chronic 318 hypertension that developed superimposed preeclampsia compared to those who did not (24% versus 6.5%; 319 p 0.02). Women with chronic hypertension who did not develop superimposed preeclampsia were also at 320 increased risk of adverse perinatal outcome compared to background incidence, but a significantly greater 321 were found across gestation in the women who did and did not develop superimposed preeclampsia; this 343 may be driven by the expected Angiotensin II inhibitory feedback on renin release, which is independent of 344 angiotensinogen substrate production. Women with preeclampsia demonstrate greater sensitivity to 345
Angiotensin II, compared with normotensive pregnant women; it is possible the cellular RAS pathway 346 through which the increased sensitivity is demonstrated, is independent of systemic substrates. (29) Biomarker variation in chronic hypertensive pregnancy studies have demonstrated that the RAAS is upregulated in normotensive pregnancy and our study confirms 348 that this upregulation occurs in both the Black and non-Black women with chronic hypertension, though it is 349 unclear if this is in response to, or the cause of other physiological changes that occur in pregnancy such as 350 increased plasma volume and vasodilation.(2) Brown and colleagues (1997) performed a cross-sectional 351 study and found that women diagnosed with preeclampsia had lower plasma concentrations of renin and 352 aldosterone compared to normotensive pregnant women.(7) Another longitudinal study by August and 353 colleagues (1990) Increased urinary AGTCR were found across gestation in women who developed superimposed preeclampsia 363 compared to those who did not. Pathological upregulation of the intrarenal RAS in preeclampsia would be 364 consistent with findings outside pregnancy; an activated intrarenal RAS has been reported in the progression 365 of renal injury in diabetic and membranous nephropathy.(28) However, our findings do not agree with a 366 cross-sectional study reported by Yilmaz and colleagues (2009) , who compared time-of-disease AGTCR in 30 367 women with preeclampsia with 30 normotensive pregnant women. They found that urinary AGTCR were 368 lower in women with preeclampsia,(49) which may represent variation specific to their sample. This study 369 did, however, report a positive correlation between urinary AGTCR, high blood pressure and proteinuria, and 370 concluded that 'local RAS activation in the kidneys may be one of the contributing factors in the 371 development of preeclampsia'.(49) In this respect our findings concur, but further investigation is required 372 to establish the importance of the intrarenal RAS in the pathophysiology of superimposed preeclampsia. 373 PCR and ACR were higher across gestation in women with chronic hypertension who developed subsequent 375 superimposed preeclampsia compared to those who did not. This may represent underlying nephropathy in 376 this group of women with chronic hypertension, as described by Crews and colleagues (2010).(16) However, 377
another study by Poon and colleagues (2008) found higher first trimester ACR was associated with 378 subsequent development of preeclampsia,(36) so it may be that the association of higher PCR/ACR from the 379 first trimester is indicative of endothelial dysfunction with subsequent development of superimposed 380 preeclampsia. The clinical utility of these findings are unclear, as proteinuria is known to increase in 381 normotensive pregnancy and identifying when protein excretion is abnormal is problematic. (18, 32) It is also 382 notable that the mean PCR and ACR values across gestation in the women in our cohort who developed 383 subsequent superimposed preeclampsia were below 30 mg/mmol and 8 mg/mmol respectively (prior to 384 diagnosis), which are currently utilised for clinical diagnosis.(47) 385
386
In this study, the proportion of the Black women developing superimposed preeclampsia was lower than the 387 proportion of non-Black women (14% versus 30%; p=0.07), though this was not significant and may relate in 388 part to the higher proportion of multiparous women in the Black group. The significant difference in booking 389 and mean post-enrollment diastolic blood pressures in women of Black ethnicity, compared to non-Black, 390 suggests potential ethnic variation in disease severity, which has been demonstrated in the non-pregnant 391 population. (11, 21, 26) Variation in the systemic RAAS may play a role in ethnic disparity in disease severity; 392 the incidence of SPE in Black women is lower within this cohort compared to the increased incidence of SPE 393 in Black women observed in other cohorts and this may have had an impact on the findings of these 394 analyses. Our study has highlighted differences in the RAAS, in particular a third trimester increase in 395 aldosterone concentrations that is present in the non-Black women, but not in the Black women and these 396 
Biomarker variation in chronic hypertensive pregnancy
The strengths of this study include multicentre recruitment of a wide ethnic mixture of women with chronic 399 hypertension in pregnancy. Longitudinal sampling has allowed assessment of variation of biomarkers across 400 gestation prior to development of adverse outcome. In contrast, a limitation of the study was the absence of 401 time-of-disease sampling, preventing comparison of each biomarker at the time of clinical diagnosis of 402 superimposed preeclampsia, and the findings of this study would require validation in a much larger cohort. 403
The high proportion of women with diabetes in this cohort may also have impacted the results of analysis A 404 and it is not possible to fully elucidate the potential impact of hyperglycaemia on our findings. Additionally, 405 although some participants may have had white coat hypertension, 24-hour ambulatory monitoring is not 406 routinely performed during pregnancy and would usually only have been confirmed after pregnancy. The incidence of chronic hypertension in pregnancy is increasing with rising maternal age and obesity. The 414 prevalence of chronic hypertension in women aged below 50 years is greater in those of Black ethnicity, 415 compared to other ethnicities. Adverse maternal and perinatal outcomes are associated with chronic 416 hypertension and the mechanisms behind these increased risks are poorly understood. In this study, changes 417 in placental and renal biomarkers predate development of superimposed preeclampsia. Low plasma PlGF 418 has a strong association with subsequent fetal growth restriction in women with chronic hypertension and 419 ethnic variation in RAAS biomarkers may relate to disparity in outcome. Further research into the physiology 420 underpinning these differences is warranted. 
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